Prospective observation study for combination therapy of Docetaxel and Ramucirumab after immunochemotherapy in advanced non-small cell lung cancer patients
Not Applicable
- Conditions
- on small cell lung cac
- Registration Number
- JPRN-UMIN000044807
- Lead Sponsor
- Kyoto Prefectural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with a history of treatment with systemic chemotherapy after combination therapy with immune checkpoint inhibitors and chemotherapy 2) Patients with active multiple cancers (hormone therapy for prostate cancer and breast cancer is acceptable) (3)Other patients who are deemed inappropriate by the physician in charge
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method